Rituximab therapy in nephrotic syndrome: Implications for patients' management

Nature Reviews Nephrology

Volumn 9, Issue 3, 2013, Pages 154-169

  Sinha, Aditi ^a   Bagga, Arvind ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; B7 ANTIGEN; CALCINEURIN INHIBITOR; CD19 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; LEVAMISOLE; MITOGEN ACTIVATED PROTEIN KINASE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 RECEPTOR; PHOSPHOLIPASE C; PLACEBO; PREDNISOLONE; PREDNISONE; PROTEIN TYROSINE KINASE; RECEPTOR ANTIBODY; RITUXIMAB; STEROID; TACROLIMUS;

ABDOMINAL PAIN; ANAPHYLAXIS; ANTIBODY BLOOD LEVEL; ARTHRITIS; BRONCHOSPASM; CATHETER COMPLICATION; CHILL; CONGENITAL NEPHROTIC SYNDROME; CORTICOSTEROID THERAPY; COUGHING; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPNEA; ERYTHEMA; FEVER; FLU LIKE SYNDROME; FOCAL GLOMERULOSCLEROSIS; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOTENSION; IDIOPATHIC DISEASE; IMMUNOGLOBULIN DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; KIDNEY DISEASE; MEMBRANOUS GLOMERULONEPHRITIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NEPHROTIC SYNDROME; NEPHROTOXICITY; NEUTROPENIA; NOSE OBSTRUCTION; PATHOGENESIS; PATIENT CARE; PLASMAPHERESIS; PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEINURIA; PRURITUS; RECURRENT DISEASE; RELAPSE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SEPTICEMIA; SERUM SICKNESS; SIDE EFFECT; SINGLE DRUG DOSE; SORE THROAT; STEROID DEPENDEND NEPHROTIC SYNDROME; STEROID DEPENDENT NEPHROTIC SYNDROME; SYSTEMATIC REVIEW; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCYTE DEPLETION; NEPHROTIC SYNDROME; PLASMA EXCHANGE; TREATMENT OUTCOME;

EID: 84874665114     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2012.289     Document Type: Review

References (160)

1. Amoroso, A. et al. Understanding rituximab function and resistance: implications for tailored therapy. Front. Biosci. 16, 770-782 (2011).
2. Ejaz, A. A., Asmar, A., Alsabbagh, M. M. & Ahsan, N. Rituximab in immunologic glomerular diseases. mAbs 4, 198-207 (2012).
3. US Food and Drug Administration. News and events [online], http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm251946.htm (2012).
4. Iijima, K. Rituximab for childhood refractory nephrotic syndrome. Pediatr. Int. 53, 617-621 (2011).
5. Takei, T. & Nitta, K. Rituximab and minimal change nephrotic syndrome: a therapeutic option. Clin. Exp. Nephrol. 15, 641-647 (2011).
6. Araya, C. E. & Dharnidharka, V. R. The factors that may predict response to rituximab therapy in recurrent focal segmental glomerulosclerosis: a systematic review. J. Transplant. http://dx.doi.org/10.1155/2011/374213.
7. Appel, G. B. Rituximab in membranous nephropathy: is it a first-line treatment? J. Am. Soc. Nephrol. 23, 1280-1282 (2012).
8. Kidney Disease Improving Global Outcomes (KDIGO). General principles in the management of glomerular disease. Kidney Int. Suppl. 2, 156-162 (2012).
9. Gulati, A. et al. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. Kidney Int. 82, 1130-1135 (2012).
10. Troyanov, S. et al. Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int. 66, 1199-1205 (2004).
11. Cragg, M. S., Walshe, C. A., Ivanov, A. O. & Glennie, M. J. The biology of CD20 and its potential as a target for mAb therapy. Curr. Dir. Autoimmun. 8, 140-174 (2005).
12. Hofmeister, J. K., Cooney, D. & Coggeshall, K. M. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx and caspase 3-dependent apoptosis. Blood Cells Mol. Dis. 26, 133-143 (2000).
13. Cartron, G., Watier, H., Golay, J. & Solal-Celigny, P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 104, 2635-2642 (2004).
14. Semac, I. et al. Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Cancer Res. 63, 534-540 (2003).
15. Koyama, A., Fujisaki, M., Kobayashi, M., Igarashi, M. & Narita, M. A glomerular permeability factor produced by human T cell hybridomas. Kidney Int. 40, 453-460 (1991).
16. Vallerskog, T. et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with, S.L.E. Clin. Immunol. 122, 62-74 (2007).
17. Stasi, R. et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 112, 1147-1150 (2008).
18. Vigna-Perez, M. et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res. Ther. 8, R83 (2006).
19. Sfikakis, P. P. et al. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin. Immunol. 123, 66-73 (2007).
20. Saadoun, D. et al. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood 111, 5334-5341 (2008).
21. Sfikakis, P. P. et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand. Arthritis Rheum. 52, 501-513 (2005).
22. Tokunaga, M. et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford) 44, 176-182 (2005).
23. Hu, C. Y. et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J. Clin. Invest. 117, 3857-3867 (2007).
24. Araya, C. et al. T regulatory cell function in idiopathic minimal lesion nephrotic syndrome. Pediatr. Nephrol. 24, 1691-1698 (2009).
25. Le Berre, L. et al. Induction of T regulatory cells attenuates idiopathic nephrotic syndrome. J. Am. Soc. Nephrol. 20, 57-67 (2009).
26. H17 cells and FOXP3 regulate T cells (Treg) in children with primary nephrotic syndrome. Pediatr. Nephrol. 24, 1683-1690 (2009).
27. +; regulatory T cells in peripheral blood mononuclear cells of primary nephrotic syndrome in children [Chinese]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 26, 783-786 (2010).
28. Bertelli, R. et al. Failure of regulation results in an amplified oxidation burst by neutrophils in children with primary nephrotic syndrome. Clin. Exp. Immunol. 161, 151-158 (2010).
29. Shimada, M. et al. Minimal change disease: a "two-hit" podocyte immune disorder? Pediatr. Nephrol. 26, 645-649 (2011).
30. Fervenza, F. C. et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin. J. Am. Soc. Nephrol. 5, 2188-2198 (2010).
31. Yeo, W. S. et al. Effect of rituximab on T-cell subsets in nephrotic children with focal segmental glomerulosclerosis (FSGS) [abstract F-PO1277]. J. Am. Soc. Nephrol. 21, 403 (2010).
32. Lin, C. Y. Immune modulatory mechanism of rituximab in steroid refractory heavy proteinuria [abstract SA-PO377]. J. Am. Soc. Nephrol. 23, 724 (2012).
33. Perosa, F., Favoino, E., Caragnano, M. A. & Dammacco, F. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood 107, 1070-1077 (2006).
34. Bezombes, C. et al. Rituximab antiproliferative effect in B lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 104, 1166-1173 (2004).
35. Fornoni, A. et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci. Transl. Med. 3, 85-95 (2011).
36. Tan, R. et al. Nef interaction with actin compromises human podocyte actin cytoskeletal integrity. Exp. Mol. Pathol. 94, 51-57 (2013).
37. Wei, C. et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat. Med. 17, 952-960 (2011).
38. REG cells [abstract FR-PO483]. J. Am. Soc. Nephrol. 23, 484 (2012).
39. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01573533 (2012).
40. REG imbalance in adult patients with minimal change nephrotic syndrome. Clin. Immunol. 139, 314-320 (2011).
41. Ng, C. M., Bruno, R., Combs, D. & Davies, B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J. Clin. Pharmacol. 45, 792-801 (2005).
42. Breedveld, F. et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J. Clin. Pharmacol. 47, 1119-1128 (2007).
43. Berinstein, N. L. et al. Association of serum rituximab (IDEC-C2B8) concentration and antitumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 9, 995-1001 (1998).
44. Kamei, K. et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr. Nephrol. 24, 1321-1328 (2009).
45. Fervenza, F. C. et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 73, 117-125 (2008).
46. Regazzi, M. B. et al. Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogenous clinical settings. Ther. Drug Monit. 27, 785-792 (2005).
47. Fujinaga, S. et al. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr. Nephrol. 25, 539-544 (2010).
48. Guigonis, V. et al. Rituximab treatment for severe steroid-or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr. Nephrol. 23, 1269-1279 (2008).
49. Sellier-Leclerc, A. L. et al. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr. Nephrol. 25, 1109-1115 (2010).
50. Ito, S. et al. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome. Pediatr. Nephrol. http://dx.doi.org/10.1007/ s00467-012-2319-1.
51. Sellier-Leclerc, A. L. et al. Rituximab in steroid dependent idiopathic nephrotic syndrome in childhood: follow-up after CD19 recovery. Nephrol. Dial. Transplant. 27, 1083-1089 (2012).
52. Gulati, A. et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and-dependent nephrotic syndrome: multicentric report. Clin. J. Am. Soc. Nephrol. 5, 2207-2212 (2010).
53. Hoxha, E., Stahl, R. A. & Harendza, S. Rituximab in adult patients with immunosuppressive-dependent minimal change disease. Clin. Nephrol. 76, 151-158 (2011).
54. Prytula, A. et al. Rituximab in refractory nephrotic syndrome. Pediatr. Nephrol. 25, 461-468 (2010).
55. Kemper, M. J. et al. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol. Dial. Transplant. 27, 1910-1915 (2012).
56. Bagga, A. & Mantan, M. Nephrotic syndrome in children. Indian J. Med. Res. 122, 13-28 (2005).
57. Kidney Disease Improving Global Outcomes (KDIGO). Steroid-sensitive nephrotic syndrome in children. Kidney Int. Suppl. 2, 163-171 (2012).
58. Hodson, E. M., Willis, N. S. & Craig, J. C. Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD002290. http://dx.doi.org/10.1002/14651858. CD002290.pub3.
59. Ishikura, K. et al. Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial. Kidney Int. 73, 1167-1173 (2008).
60. Benz, K., Dötsch, J., Rascher, W. & Stachel, D. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr. Nephrol. 19, 794-797 (2004).
61. Sugiura, H. et al. Effect of single-dose rituximab on primary glomerular diseases. Nephron Clin. Pract. 117, c98-c105 (2011).
62. Kisner, T., Burst, V., Teschner, S., Benzing, T. & Kurschat, C. E. Rituximab treatment for adults with refractory nephrotic syndrome: a singlecenter experience and review of the literature. Nephron Clin. Pract. 120, c79-c85 (2012).
63. Ochi, A. et al. Rituximab treatment for adult patients with focal segmental glomerulosclerosis. Intern. Med. 51, 759-762 (2012).
64. Sinha, A., Bhatia, D., Gulati, A., Hari, P. & Bagga, A. Efficacy and safety of rituximab in difficult steroid resistant & dependent nephrotic syndrome [abstract OP64]. Pediatr. Nephrol. 27, 1605-1829 (2012).
65. Ravani, P. et al. Short-term effects of rituximab in children with steroid-and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin. J. Am. Soc. Nephrol. 6, 1308-1315 (2011).
66. Magnasco, A. et al. Rituximab in children with resistant idiopathic nephrotic syndrome. J. Am. Soc. Nephrol. 23, 1117-1124 (2012).
67. Ito, S. et al. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr. Nephrol. 26, 1823-1828 (2011).
68. Sinha, A., Bagga, A., Gulati, A. & Hari, P. Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndrome. Pediatr. Nephrol. 27, 235-241 (2012).
69. Ruggenenti, P. et al. Rituximab in steroid-dependent or multirelapsing nephrotic syndrome of adults and children: results from the NEMO trial [abstract SA-PO375]. J. Am. Soc. Nephrol. 23, 484 (2012).
70. Japan Medical Association for Clinical Trials. Double-Blind Study of IDEC-C2B8 in patients with childhood-onset refractory nephrotic syndrome. JMACCT Clinical Trials Registry [online], https://dbcentre3.jmacct.med.or.jp/jmactr/ App/JMACTRE02-04/JMACTRE02-04. aspx?kbn=3&seqno=662 (2012).
71. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01268033 (2012).
72. Bagga, A., Sinha, A. & Moudgil, A. Rituximab in patients with the steroid-resistant nephrotic syndrome. N. Engl. J. Med. 356, 2751-2752 (2007).
73. Kurosu, N. et al. Successful use of single-dose rituximab for the maintenance of remission in a patient with steroid-resistant nephrotic syndrome. Intern. Med. 48, 1901-1904 (2009).
74. Suri, M., Tran, K., Sharma, A. P., Filler, G. & Grimmer, J. Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab. Int. Urol. Nephrol. 40, 807-810 (2008).
75. Nakayama, M. et al. Rituximab for refractory focal segmental glomerulosclerosis. Pediatr. Nephrol. 23, 481-485 (2008).
76. Peters, H. P., van de Kar, N. C. & Wetzels, J. F. Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: report of four cases and review of the literature. Neth. J. Med. 66, 408-415 (2008).
77. Fernandez-Fresnedo, G. et al. Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 4, 1317-1323 (2009).
78. Kari, J. A. et al. Rituximab for refractory cases of childhood nephrotic syndrome. Pediatr. Nephrol. 26, 733-737 (2011).
79. Kong, W. Y., Swaminathan, R. & Irish, A. Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature. Int. Urol. Nephrol. http://dx.doi.org/10.1007/s11255-012-0206-0.
80. Couser, W. Recurrent glomerulonephritis in the renal allograft: an update of selected areas. Exp. Clin. Transplant. 3, 283-288 (2005).
81. Ponticelli, C. & Glassock, R. J. Posttransplant recurrence of primary glomerulonephritis. Clin. J. Am. Soc. Nephrol. 5, 2363-2372 (2010).
82. Vinai, M., Waber, P. & Seikaly, M. G. Recurrence of focal segmental glomerulosclerosis in renal allograft: an in-depth review. Pediatr. Transplant. 14, 314-325 (2010).
83. Weber, S. et al. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int. 66, 571-579 (2004).
84. Baum, M. A. et al. Loss of living donor renal allograft survival advantage in children with focal segmental glomerulosclerosis. Kidney Int. 59, 328-333 (2001).
85. Cibrik, D. M., Kaplan, B., Campbell, D. A. & Meier-Kriesche, H. U. Renal allograft survival in transplant recipients with focal segmental glomerulosclerosis. Am. J. Transplant. 3, 64-67 (2003).
86. Hariharan, S. et al. Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). Transplantation 68, 635-641 (1999).
87. Pardon, A. et al. Risk factors and outcome of focal and segmental glomerulosclerosis recurrence in adult renal transplant recipients. Nephrol. Dial. Transplant. 21, 1053-1059 (2006).
88. Newstead, C. G. Recurrent disease in renal transplants. Nephrol. Dial. Transplant. 18 (Suppl. 6), 68-74 (2003).
89. Ponticelli, C. Recurrence of focal segmental glomerular sclerosis after renal transplantation. Nephrol. Dial. Transplant. 25, 25-31 (2010).
90. Nozu, K. et al. Rituximab treatment for posttransplant lymphoproliferative disorder induces complete remission of recurrent nephrotic syndrome. Pediatr. Nephrol. 20, 1660-1663 (2005).
91. Sakai, K. et al. Protocol biopsies for focal segmental glomerulosclerosis treated with plasma exchange and rituximab in a renal transplant patient. Clin. Transplant. 24, 60-65 (2010).
92. Kumar, J. et al. Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis. Pediatr. Nephrol. http://dx.doi.org/10.1007/ s00467-012-2314-6.
93. Tsagalis, G., Psimenou, E., Nakopoulou, L. & Laggouranis, A. Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation. Artif. Organs 35, 420-425 (2011).
94. Stewart, Z. A., Shetty, R., Nair, R., Reed, A. I. & Brophy, P. D. Case report: successful treatment of recurrent focal segmental glomerulosclerosis with a novel rituximab regimen. Transplant. Proc. 43, 3994-3996 (2011).
95. Gossmann, J. et al. Abrogation of nephrotic proteinuria by rituximab treatment in a renal transplant patient with relapsed focal segmental glomerulosclerosis. Transpl. Int. 20, 558-562 (2007).
96. Grenda, R., Jarmużek, W., Piatosa, B. & Rubik, J. Long-term effect of rituximab in maintaining remission of recurrent and plasmapheresis-dependent nephrotic syndrome post-renal transplantation-case report. Pediatr. Transplant. 15, e121-e125 (2011).
97. Audard, V. et al. Rituximab therapy prevents focal and segmental glomerulosclerosis recurrence after a second renal transplantation. Transpl. Int. 25, e62-e66 (2012).
98. Chikamoto, H. et al. Pretransplantation combined therapy with plasmapheresis and rituximab in a second living-related kidney transplant pediatric recipient with a very high risk for focal segmental glomerulosclerosis recurrence. Pediatr. Transplant. 16, e286-e290 (2012).
99. Gohh, R. Y. et al. Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am. J. Transplant. 5, 2907-2912 (2005).
100. McDonald, V., Manns, K., Mackie, I. J., Machin, S. J. & Scully, M. A. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J. Thromb. Haemost. 8, 1201-1208 (2010).
101. Glassock, R. J. Diagnosis and natural course of membranous nephropathy. Semin. Nephrol. 3, 324-332 (2003).
102. [No authors listed]. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int. 13, 159-165 (1978).
103. Beck, L. H. & Salant, D. J. Membranous nephropathy: recent travels and new roads ahead. Kidney Int. 77, 765-770 (2010).
104. Zeng, C. H. et al. Etiology and clinical characteristics of membranous nephropathy in Chinese patients. Am. J. Kidney Dis. 52, 691-698 (2008).
105. Polanco, N. et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 21, 697-704 (2010).
106. Schieppati, A. et al. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. Cochrane Database of Systematic Reviews, Issue 4. Art. No.: CD004293. http://dx.doi.org/search/site/ CD004293.
107. Kidney Disease Improving Global Outcomes (KDIGO). Idiopathic membranous nephropathy. Kidney Int. Suppl. 2, 186-197 (2012).
108. Cattran, D. C., Reich, H. N., Kim, S. J. & Troyanov, S. Have we changed the outcome in membranous nephropathy? A propensity study on the role of immunosuppressive therapy. Clin. J. Am. Soc. Nephrol. 6, 1591-1598 (2011).
109. Remuzzi, G. et al. Rituximab for idiopathic membranous nephropathy. Lancet 360, 923-924 (2002).
110. Beck, L. H. et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 361, 11-21 (2009).
111. Beck, L. H. Jr et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J. Am. Soc. Nephrol. 22, 1543-1550 (2011).
112. Hofstra, J. M., Beck, L. H. Jr, Beck, D. M., Wetzels, J. F. & Salant, D. J. Antiphospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin. J. Am. Soc. Nephrol. 6, 1286-1291 (2011).
113. Stahl, R. A. K., Hoxha, E. & Fechner, K. PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. N. Engl. J. Med. 363, 496-498 (2010).
114. Michel, P. A. et al. Rituximab treatment for membranous nephropathy: a French clinical and serological retrospective study of 28 patients. Nephron Extra 1, 251-261 (2011).
115. Murtas, C. et al. Co-existence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin. J. Am. Soc. Nephrol. http://dx.doi.org/10.2215/CJN.02170312.
116. Hoxha, E. et al. An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol. Dial. Transplant. 26, 2526-2532 (2011).
117. Bomback, A. S. et al. Rituximab therapy for membranous nephropathy: a systematic review. Clin. J. Am. Soc. Nephrol. 4, 734-744 (2009).
118. Segarra, A. et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin. J. Am. Soc. Nephrol. 4, 1083-1088 (2009).
119. Sprangers, B. et al. Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation. Clin. J. Am. Soc. Nephrol. 5, 790-797 (2010).
120. Cravedi, P. et al. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study. Am. J. Nephrol. 33, 461-468 (2011).
121. Ruggenenti, P. et al. Rituximab in idiopathic membranous glomerulonephritis, J. Am. Soc. Nephrol. 23, 1416-1425 (2012).
122. Rodriguez, E. F. et al. The pathology and clinical features of early recurrent membranous glomerulonephritis. Am. J. Transplant. 12, 1029-1038 (2012).
123. Ruggenenti, P. et al. Rituximab for idiopathic membranous nephropathy: who can benefit? Clin. J. Am. Soc. Nephrol. 1, 738-748 (2006).
124. Irazabal, M. V. et al. Low-and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study. Nephrol. Dial. Transplant. http://dx.doi.org/10.1093/ndt/ gfs379.
125. US National Library of Medicine. ClinicalTrials. gov [online], http://clinicaltrials.gov/ct2/show/NCT01180036 (2012).
126. US National Library of Medicine. ClinicalTrials. gov [online], http://www.clinicaltrials.gov/ct2/show/NCT01508468?term=NCT01508468&r ank=1 (2012).
127. Ardelean, D. S. et al. Severe ulcerative colitis after rituximab therapy. Pediatrics 126, e243-e246 (2010).
128. Strologo, D. L. et al. Use of rituximab in focal glomerulosclerosis relapses after renal transplantation. Transplantation 88, 417-420 (2009).
129. Atmar, J. Review of the safety and feasibility of rapid infusion of rituximab. J. Oncol. Practice 6, 91-93 (2010).
130. Kamar, N. et al. Treatment of focal segmental glomerular sclerosis with rituximab: 2 case reports. Clin. Nephrol. 67, 250-254 (2007).
131. Bayrakci, U. S., Baskin, E., Sakalli, H., Karakayali, H. & Haberal, M. Rituximab for post-transplant recurrences of FSGS. Pediatr. Transplant. 13, 240-243 (2009).
132. Thevenin, C., Lucas, B. P., Kozlow, E. J. & Kehrl, J. H. Cell type-and stage-specific expression of the CD20/B1 antigen correlates with the activity of a diverged octamer DNA motif present in its promoter. J. Biol. Chem. 268, 5949-5956 (1993).
133. Lim, S. H. et al. B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period. Leuk. Lymphoma 49, 152-153 (2008).
134. Wang, Q. S. et al. Change of serum immunoglobulin level in patients with diffuse large B cell lymphoma after rituximab combined with chemotherapy [Chinese]. Zhongguo Shi Yan Xue Ye Za Zhi 19, 676-679 (2011).
135. Cooper, N., Davies, E. G. & Thrasher, A. J. Repeated course of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin. Br. J. Haematol. 146, 120-122 (2009).
136. Lee, Y. H., Bae, S. C. & Song, G. G. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Rheumatol. Int. 31, 1493-1499 (2011).
137. Lanini, S. et al. Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. BMC Med. 9, 36 (2011).
138. Vidal, L. et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J. Natl Cancer Inst. 103, 1799-1806 (2011).
139. Aksoy, S., Dizdar, O., Hayran, M. & Harputluoǧlu, H. Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis. Leuk. Lymphoma 50, 357-365 (2009).
140. Sato, M. et al. Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome. Pediatr. Nephrol. 1, 145-149 (2013).
141. Teichmann, L. L. et al. Fatal Pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. Rheumatology (Oxford) 47, 1256-1257 (2008).
142. Podolskaya, A., Stadermann, M., Pilkington, C., Marks, S. D. & Tullus, K. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch. Dis. Child. 93, 401-406 (2008).
143. Kahwaji, J. et al. Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin. Clin. J. Am. Soc. Nephrol. 6, 2894-2900 (2011).
144. Kamar, N. et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am. J. Transplant. 10, 89-98 (2010).
145. Tsutsumi, Y. et al. Rituximab administration and reactivation of, H. B. V. Hepat. Res. Treat. http://dx.doi.org/10.1155/2010/182067.
146. Mastroianni, C. M. et al. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J. Gastroenterol. 17, 3881-3887 (2011).
147. Bennett, C. L. Pharmacovigilance and PML in the oncology setting. Clin. J. Med. 78 (Suppl. 2), S13-S17 (2011).
148. US Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Rituxan (rituximab)-PML [online], http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm187791 (2012).
149. Delbue, S. et al. Investigation of polyomaviruses replication in pediatric patients with nephropathy receiving rituximab. J. Med. Virol. 84, 1464-1470 (2012).
150. Herishanu, Y. et al. Fatal interstitial pneumonitis related to rituximab-containing regimen. Clin. Lymphoma Myeloma 6, 407-409 (2006).
151. Hadjinicolaou, A. V., Nisar, M. K., Parfrey, H., Chilvers, E. R. & Ostor, A. J. Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology (Oxford) 51, 653-662 (2012).
152. Bitzan, M., Anselmo, M. & Carpineta, L. Rituximab (B-cell depleting antibody) associated lung injury (RALI): pediatric case and systematic review of the literature. Pediatr. Pulmonol. 44, 922-934 (2009).
153. Chaumais, M. et al. Fatal pulmonary fibrosis after rituximab administration. Pediatr. Nephrol. 24, 1753-1755 (2009).
154. Ergin, A. B., Fong, N. & Daw, H. A. Rituximab-induced bronchiolitis obliterans organizing pneumonia. Case Reports Med. http://dx.doi.org/10.1155/ 2012/680431.
155. Albert, D. et al. Variability in the biological response to anti-CD20 B-cell depletion in systemic lupus erythematosus. Ann. Rheum. Dis. 67, 1724-1731 (2008).
156. Igarashi, T. et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann. Oncol. 13, 928-943 (2002).
157. Lunardon, L. & Payne, A. S. Inhibitory human antichimeric antibodies to rituximab in a patient with pemphigus. J. Allergy Clin. Immunol. 130, 800-803 (2012).
158. Looney, R. J. et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50, 2580-2589 (2004).
159. Davis, T. A. et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol. 18, 3135-3143 (2000).
160. Robak, T. & Robak, E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. BioDrugs 25, 13-25 (2011).